Disease Areas:
Cough, IPFDevice Types:
VitaloJAKDOI:
10.1007/s00408-025-00854-yThis randomized, placebo-controlled, Phase 2a trial will examine the safety and efficacy of suplastast tosilate (ME‑015) in ~40 patients with IPF and chronic cough. Endpoints of the trial include cough frequency, which will be measured using the Vitalograph VitaloJAK cough monitor.
